Osimertinib suitable for first line EGFRm lung cancer

Dr Ramalingam talks with ecancer at ESMO 2017 Congress in Madrid about the results of the double blind, randomised FLAURA trial, looking at the use of osimertinib versus the existing standard of care for patients with EGFR mutated lung cancer. He...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2xlrjy6
via IFTTT